X4 Pharmaceuticals
XFOR
51 hedge funds and large institutions have $85.7M invested in X4 Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 20 reducing their positions, and 17 closing their positions.
593% more call options, than puts
Call options by funds: $416K | Put options by funds: $60K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.06% less ownership
Funds ownership: 2.23% → 2.17% (-0.06%)
18% less funds holding
Funds holding: 62 → 51 (-11)
20% less capital invested
Capital invested by funds: $108M → $85.7M (-$22M)
60% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 20
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$4.41M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.24M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$544K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$284K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$201K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.59M |
| 2 |
A
Abingworth
London,
United Kingdom
|
-$1.49M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$984K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$694K |
| 5 |
Millennium Management
New York
|
-$651K |
XFOR Hedge Fund Activity: Q3 2021 in Review
51 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q3 2021, worth a combined $85.7M — down 20% from $108M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of XFOR and 6 opened new positions — a net loss of 11 holders — while 20 trimmed existing stakes and 8 added.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $4.41M. The largest seller was Driehaus Capital Management, cutting an estimated $1.59M.
- 51 institutional investors held X4 Pharmaceuticals (XFOR) as of Q3 2021, down from 62 in Q2 2021.
- Funds reported $85.7M of X4 Pharmaceuticals stock for Q3 2021, down 20% quarter-over-quarter.
- 6 funds opened new X4 Pharmaceuticals positions in Q3 2021 and 17 closed out, a net change of -11 holders.
- The largest X4 Pharmaceuticals buyer in Q3 2021 was Altium Capital Management, an estimated $4.41M added.
- The largest X4 Pharmaceuticals seller in Q3 2021 was Driehaus Capital Management, an estimated $1.59M sold.
Based on aggregated 13F filings for Q3 2021.